GLUE
Monte Rosa Therapeutics Inc

1,458
Mkt Cap
$1.35B
Volume
2,954.00
52W High
$25.77
52W Low
$3.50
PE Ratio
58.12
GLUE Fundamentals
Price
$17.75
Prev Close
$18.50
Open
$18.08
50D MA
$19.71
Beta
1.52
Avg. Volume
2.69M
EPS (Annual)
-$0.9836
P/B
4.46
Rev/Employee
$564,343.28
$183.50
Loading...
Loading...
News
all
press releases
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by GSA Capital Partners LLP
GSA Capital Partners LLP decreased its position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 53.0% during the 3rd quarter, according to the company in its most recent 13F...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of +57.90% and +0.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 7,664,016 shares...
MarketBeat·15d ago
News Placeholder
Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold
Zacks Research lowered Monte Rosa Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday...
MarketBeat·24d ago
News Placeholder
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, MarketBeat...
MarketBeat·25d ago
News Placeholder
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Drop in Short Interest
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling...
MarketBeat·29d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9% - What's Next?
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9% - Should You Sell...
MarketBeat·1mo ago
News Placeholder
51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC
Campbell & CO Investment Adviser LLC acquired a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 3rd quarter, according to its most recent 13F filing with...
MarketBeat·1mo ago
News Placeholder
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 8,454,052...
MarketBeat·1mo ago
News Placeholder
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm...
MarketBeat·2mo ago
<
1
2
...
>

Latest GLUE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.